NCoBC 2024
National Consortium of Breast Centers
Booth 406 | Las Vegas, NV | March 15 – March 20, 2024
Discover the ProFound Breast AI Health Suite
Together, we can change more lives.
Backed by science, clinical evidence, and proven patient outcomes, our suite of solutions – Detection, Density, and Risk – shine a spotlight on cancer, exposing its hiding place. Empowering you to personalize breast cancer screening like never before.
Cancer wins when it hides.
When it comes to cancer, hide and seek is no game.
iCAD is creating a world where cancer can’t hide with innovative artificial intelligence solutions that empower providers and professionals to accurately, reliably and quickly detect cancer and improve outcomes – optimizing every patient’s opportunity to live better, longer lives.
Join us for a Breakfast Symposium
General Session (Vendome) • Monday, March 18th • 7:00-7:45am
Title: Revolutionizing Cancer Care: The Role of AI in Breast Imaging
Speaker: Nikki Gidwaney, MD, Radiologist, Stony Brook University Hospital
Description: Discover how comprehensive breast-imaging centers are staying at the forefront with best-in-class AI cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment solutions.
Joining forces against a common enemy.
In the fight against cancer, we’re stronger together. Learn why our customers believe that our solutions are the secret weapon for cancer detection and treatment.
“Our retrospective study shows that AI has the potential to correctly identify a third of DBT screening exams as having no malignancy or an extremely low likelihood of malignancy. This AI-triaging could help radiologists determine which cases may need more intensive analysis”.
EMILY F. CONANT
Professor of Radiology and Vice Chair of Faculty Development in the Department of Radiology at the University of Pennsylvania, Perelman School of Medicine
“ProFound AI is a game-changer, helping us more confidently and efficiently move through cases, and with more accuracy than ever before. Whether recommending a biopsy or confidently dismissing a case, ProFound AI empowers our team with crucial insights that aid in clinical decisions”.
LAURA H. DEAN, MD
Radiologist, Section of Breast Imaging, Cleveland Clinic
“ProFound AI has provided a great deal of assistance in mammography decisions. ProFound AI uses artificial intelligence to rapidly and accurately analyze patients’ digital breast tomosynthesis images, producing a unique and quantifiable Certainty of Finding score for the patients’ overall case”.
KATHY SCHILLING, MD
Radiologist, Boca Raton Regional Hospital
Introducing iCAD’s AI Platform
ProFound Breast Health Suite
Powered by the latest innovations in artificial intelligence (AI), the ProFound Suite offers clinically proven, 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation. With about 2x the improvement in clinical performance compared to other leading offers,1 ProFound offers unrivaled accuracy, as well as multi‐vendor compatibility and unique workflow advantages.
Why early detection matters.
• Increases the five-year survival rate to over 99%.2
• Reduce the need for aggressive treatments.
• Better treatment outcomes.
Patient-Driven, AI-Powered.
Creating a World Where Cancer Can’t Hide.
Flexible integrations to maximize patient care.
Streamlining mammography workflows to create efficiencies and peace of mind.
With thousands of installations worldwide, our solutions offer multi-vendor compatibility that seamlessly integrate into the diagnostic process, in any reading environment.
Implementation and operation made easy.
Multi-Vendor Capability
Fully integrated with:
• 50+ PACS and 94 versions
• 2D and 3D OEM manufacturers
• AI platform providers and workflow systems
Multi-Deployment Options
• Cloud – yours or ours
• On-premises hardware – yours or ours
• 3rd party Platform or OEM integration
Reserve time in-person or virtually.
We look forward to meeting with you.
Let us show you our suite of clinically proven AI-powered breast cancer detection, density assessment, and risk evaluation solutions provide certainty and peace of mind, improving patient outcomes and saving lives.
Disclaimer:
• ProFound AI (new 4th generation) is pending CE Mark, Health Canada, and FDA Clearance.
• ProFound AI Risk is CE Marked, Health Canada Licensed, and available for investigational use only in the U.S.
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 1-20-23. FDA 510K submissions K182373 (iCAD), K201019 (Hologic) and K193229 (ScreenPoint).
- https://www.nationalbreastcancer.org/early-detection-of-breast-cancer. Accessed 11-01-2023